Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin

Neuro-Ophthalmology

Volumn 34, Issue 1, 2010, Pages 20-35

  Sergott, Robert C ^a   Wheless, James W ^b   Smith, Michael C ^c   Westall, Carol A ^d   Kardon, Randy H ^e   Arnold, Anthony ^f   Foroozan, Rod ^g   Sagar, Stephen M ^h  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c RUSH UNIVERSITY   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF IOWA   (United States)

^f JULES STEIN EYE INSTITUTE   (United States)

^g CULLEN EYE INSTITUTE   (United States)

^h LUNDBECK RESEARCH USA   (United States)

Author keywords

Complex partial seizures; Infantile spasms; Retinopathy; Vigabatrin; Visual field defect

Indexed keywords

VIGABATRIN;

COMPLEX PARTIAL SEIZURE; EVIDENCE BASED MEDICINE; FUNCTION TEST; HUMAN; INFANTILE SPASM; OPTIC NERVE ATROPHY; PERIMETRY; PROGNOSIS; RETINA ARTERY OCCLUSION; RETINA MACULOPATHY; RETINOPATHY; REVIEW; RISK FACTOR; VISION; VISION TEST; VISUAL FIELD DEFECT; VISUAL FUNCTION TEST;

EID: 76449091489     PISSN: 01658107     EISSN: 1744506X     Source Type: Journal    
DOI: 10.3109/01658100903582498     Document Type: Review

References (70)

1. Ben-Menachem E. Vigabatrin. Epilepsia 1995;36 Suppl 2:S95-104.
2. Bruni J, Guberman A, Vachon L, Desforges C. Vigabatrin as add-on therapy for adult complex partial seizures: A double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure 2000;9:224-232.
3. French JA, Mosier M, Walker S, et al. A double-blind, placebo- controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. Neurology 1996;46:54-61.
4. Guberman A, Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 2000;9:112-118.
5. Sander JW, Trevisol-Bittencourt PC, Hart YM, Shorvon SD. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J Neurol Neurosurg Psychiatry 1990;53:1008-1010.
6. Aicardi J, Mumford J, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: A European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia 1996;37:638-642.
7. Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999;40:1627-1633.
8. Chiron C, Dulac O, Luna D, et al. Vigabatrin in infantile spasms. Lancet 1990;335:363-364.
9. Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infan tile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26:389-395.
10. Elterman RD, Shields WD, Mansfield KA, Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001;57:1416-1421.
11. Wohlrab G, Boltshauser E, Schmitt B. Vigabatrin as a firstline drug in West syndrome: Clinical and electroencephalographic outcome. Neuropediatrics 1998;29:133-136.
12. Kramer U, Nevo Y, Neufeld MY, et al. Epidemiology of epilepsy in childhood: A cohort of 440 consecutive patients. Pediatr Neurol 1998;18:46-50.
13. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
14. Sperling MR. The consequences of uncontrolled epilepsy. CNS Spectr 2004;9:98-101, 6-9.
15. Wheless JW. Intractable epilepsy: A survey of patients and caregivers. Epilepsy Behav 2006;8:756-764.
16. Sabril full Prescribing Information. Deerfield, IL: Lundbeck, Inc.; August 2009.
17. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Bmj 1997; 314:180-181.
18. Harding GF.Severe persistent visual field constriction associated with vigabatrin. Benefit: Risk ratio must be calculated for individual patients. Bmj 1998;316:232-233.
19. Wilson EA, Brodie MJ.Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions. Bmj 1997;314:1693.
20. Baulac M, Nordmann JP, Lanoe Y. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents. Lancet 1998;352:546.
21. Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999;67:716-722.
22. Kalviainen R, Nousiainen I. Visual field defects with vigabatrin: Epidemiology and therapeutic implications. CNS Drugs 2001;15:217-230.
23. Nicolson A, Leach JP, Chadwick DW, Smith DF. The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 2002;73:327-329.
24. Wild JM, Martinez C, Reinshagen G, Harding GF. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999;40:1784-1794.
25. Vanhatalo S, Nousiainen I, Eriksson K, et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2002;43:748-756.
26. Hardus P, Verduin WM, Postma G, et al. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 2000;41:581-587.
27. Besch D, Kurtenbach A, Apfelstedt-Sylla E, et al. Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 2002;104:151-170.
28. Newman WD, Tocher K, Acheson JF. Vigabatrin associated visual field loss: A clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 2002; 16:567-571.
29. Kalviainen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:922-926.
30. Stefan H, Bernati, K, Knorr, HLJ. Visual field constriction and anti-epileptic drug treatment. Neurol Psychiat Brain Research 2000;7:185-190.
31. Schmitz B, Schmidt T, Jokiel B, et al. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: A prospective study. J Neurol 2002; 249:469-475.
32. Wild JM, Ahn HS, Baulac M, et al. Vigabatrin and epilepsy: Lessons learned. Epilepsia 2007;48:1318-1327.
33. Guidelines for visual field screening: Visual field defects and vigabatrin. Aventis Pharma Ltd. Jan 2000.
34. Royal College of Ophthalmologists. The Ocular Side Effects of Vigabatrin (Sabril): Information and Guidance for Screening. Published March 2008. Available at: http://www. rcophth.ac.uk/docs/publications/published-guidelines/ Vigabatrin-Guidelines-March-2008.pdf. Accessed May 17, 2008.
35. Gross-Tsur V, Banin E, Shahar E, et al. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000;48:60-64.
36. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
37. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings. Neurology 1999;53:2082-2087.
38. Ruether K, Pung T, Kellner U, et al. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 1998; 116:817-819.
39. Durbin S, Mirabella G, Buncic JR, Westall CA. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy. Invest Ophthalmol Vis Sci 2009; Epub ahead of print.
40. McDonagh J, Stephen LJ, Dolan FM, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003;61:1690-1694.
41. Buncic JR, Westall CA, Panton CM, et al. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 2004;111:1935-1942.
42. Harding GF, Wild JM, Robertson KA, et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin- attributed visual field constriction. Epilepsia 2000; 41:1420-1431.
43. Durnian JM, Clearkin LG. Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss- could scanning laser polarimetry aid diagnosis? Eye 2008; 22:559-563.
44. Lawthom C, Smith PE, Wild JM. Nasal retinal nerve fiber layer attenuation: A biomarker for vigabatrin toxicity. Ophthalmology 2009;116:565-571.
45. Jammoul F, Wang Q, Nabbout R, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 2009;65:98-107.
46. Frisen L, Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 2003;81:466-473.
47. Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999;106:1792-1798.
48. Choi HJ, Kim DM. Visual field constriction associated with vigabatrin: Retinal nerve fiber layer photographic correlation. J Neurol Neurosurg Psychiatry 2004;75:1395.
49. Wild JM, Robson CR, Jones AL, et al. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 2006;47:917-924.
50. Hardus P, Verduin W, Berendschot T, et al. Vigabatrin: Longterm follow-up of electrophysiology and visual field examinations. Acta Ophthalmol Scand 2003; 81:459-465.
51. Best JL, Acheson JF. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication. Eye 2005;19:41-44.
52. Nousiainen I, Mantyjarvi M, Kalviainen R. No reversion in vigabatrin-associated visual field defects. Neurology 2001;57:1916-1917.
53. Malmgren K, Ben-Menachem E, Frisen L. Vigabatrin visual toxicity: Evolution and dose dependence. Epilepsia 2001;42:609-615.
54. Manuchehri K, Goodman S, Siviter L, Nightingale S. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 2000;84:499-505.
55. Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: Quantification and relation to dosage. Epilepsia 2001;42:262-267.
56. Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008;49:108-116.
57. Arndt CF, Salle M, Derambure PH, et al. The effect on vision of associated treatments in patients taking vigabatrin: Carbamazepine versus valproate. Epilepsia 2002;43:812-817.
58. Lawden MC. Vigabatrin-associated visual field constriction: A review. Optometry in Practice 2006;7:1-14.
59. ADRAC. Update on visual field constriction with vigabatrin. Aust Adv Drug Reactions Bull 1999;18:3.
60. Westall C, Nobile, R. Age of onset of treatment in children with infantile spasms contributes to worsening of ERGs in children with infantile spasms taking the antiepileptic drug vigabatrin? Doc Ophthalmol 2006;112:87.
61. Graniewski-Wijnands HS, van der Torren K. Electro-ophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol 2002;104:189-194.
62. Acheson JF. Vigabatrin associated visual field constriction. J Neurol Neurosurg Psychiatry 1999;67:707-708.
63. Krakow K, Polizzi G, Riordan-Eva P, et al. Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 2000;9:287-290.
64. Vanhatalo S, Alen R, Riikonen R, et al. Reversed visual field constrictions in children after vigabatrin withdrawal-True retinal recovery or improved test performance only? Seizure 2001;10:508-511.
65. Harding GF.Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist. Bmj 1997;314:1694.
66. Cohen S, Kawasaki, A. Introduction to formal visual field testing: Goldmann and Humphrey perimetry. J Ophthal Nursing Tech 1999;18:7-11.
67. Esterman B.Grid for scoring visual fields. II. Perimeter. Arch Ophthalmol 1968;79:400-406.
68. Harding GF, Spencer EL, Wild JM, et al. Field-specific visual- evoked potentials: Identifying field defects in vigabatrintreated children. Neurology 2002;58:1261-1265.
69. Harding GF, Wild JM, Robertson KA, et al. Separating the retinal electrophysiologic effects of vigabatrin: Treatment versus field loss. Neurology 2000;55:347-352.
70. Harding GF, Robertson KA, Edson AS, et al. Visual electrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol 1998;97:179-188.